Treatment of hepatitis C virus infection in patients with CKD

被引：5
作者：
Chan, Henry Lik-Yuen [1 ]
Li, Philip Kam-Tao [2 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Carol & Richard Yu PD Res Ctr, Shatin, Hong Kong, Peoples R China
来源：
NATURE REVIEWS NEPHROLOGY | 2016年 / 12卷 / 01期
关键词：
DIALYSIS PATIENTS; HCV; RIBAVIRIN; DASABUVIR; THERAPY; SAFETY;
D O I：
10.1038/nrneph.2015.189
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) can be challenging. Now, data from the phase III C-SURFER study show that grazoprevir and elbasvir-a new all-oral combination therapy for HCV-is safe and effective in patients with stage 4-5 CKD.
引用
收藏
页码：5 / 6
页数：2
相关论文
共 10 条
  • [1] Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies
    Fabrizi, F.
    Dixit, V.
    Messa, P.
    Martin, P.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2014, 21 (10) : 681 - 689
  • [2] Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?
    Fabrizi, F.
    Dixit, V.
    Messa, P.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2012, 19 (09) : 601 - 607
  • [3] ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
    Ferenci, Peter
    Bernstein, David
    Lalezari, Jacob
    Cohen, Daniel
    Luo, Yan
    Cooper, Curtis
    Tam, Edward
    Marinho, Rui T.
    Tsai, Naoky
    Nyberg, Anders
    Box, Terry D.
    Younes, Ziad
    Enayati, Pedram
    Green, Sinikka
    Baruch, Yaacov
    Bhandari, Bal Raj
    Caruntu, Florin Alexandru
    Sepe, Thomas
    Chulanov, Vladimir
    Janczewska, Ewa
    Rizzardini, Giuliano
    Gervain, Judit
    Planas, Ramon
    Moreno, Christophe
    Hassanein, Tarek
    Xie, Wangang
    King, Martin
    Podsadecki, Thomas
    Reddy, K. Rajender
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (21) : 1983 - 1992
  • [4] International Society of Nephrology, 2008, KIDNEY INT S, V109, pS1
  • [5] Infectious complications in dialysis -epidemiology and outcomes
    Li, Philip Kam-Tao
    Chow, Kai Ming
    [J]. NATURE REVIEWS NEPHROLOGY, 2012, 8 (02) : 77 - 88
  • [6] SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR FOR TREATING HCV GT1 INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE: THE RUBY-I STUDY
    Pockros, P. J.
    Reddy, K. R.
    Mantry, P. S.
    Cohen, E.
    Bennett, M.
    Sulkowski, M. S.
    Bernstein, D.
    Podsadecki, T.
    Cohen, D.
    Shulman, N. S.
    Wang, D.
    Khatri, A.
    Abunimeh, M.
    Lawitz, E.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S257 - S257
  • [7] Roth D., 2015, LANCET, V386, P17
  • [8] SAFETY AND EFFICACY OF SOFOSBUVIR-CONTAINING REGIMENS IN HEPATITIS C INFECTED PATIENTS WITH REDUCED RENAL FUNCTION: REAL-WORLD EXPERIENCE FROM HCV-TARGET
    Saxena, V.
    Koraishy, F. M.
    Sise, M.
    Lim, J. K.
    Chung, R. T.
    Liapakis, A.
    Nelson, D. R.
    Schmidt, M.
    Fried, M. W.
    Terrault, N.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S267 - S267
  • [9] Webster DP, 2015, LANCET, V385, P1124, DOI [10.1016/S0140-6736(14)62401-6, 10.1016/S0140-6736(14)61932-2]
  • [10] Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
    Zeuzem, Stefan
    Ghalib, Reem
    Reddy, K. Rajender
    Pockros, Paul J.
    Ben Ari, Ziv
    Zhao, Yue
    Brown, Deborah D.
    Wan, Shuyan
    DiNubile, Mark J.
    Bach-Yen Nguyen
    Robertson, Michael N.
    Wahl, Janice
    Barr, Eliav
    Butterton, Joan R.
    [J]. ANNALS OF INTERNAL MEDICINE, 2015, 163 (01) : 1 - 13
1